Approval marks continued progress in expanding reimbursement pathways and accelerating access to advanced personal exoskeleton technology for individuals with spinal cord injury.MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received its first prior authorization from ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) Israel Not applicable (State or other jurisdiction of incorporatio ...

Core Insights - Spanish airline Iberia plans to significantly expand its operations in Brazil for the second consecutive year in 2026, driven by the introduction of new Airbus jets [1] Company Expansion Plans - Iberia aims to open more routes in Brazil, capitalizing on the growth potential in Latin America's large market [1]

Financial Data and Key Metrics Changes - Lifeward reported revenue of $6.2 million in Q3 2025, a slight increase of approximately 1.1% from $6.1 million in Q3 2024, and an 8% increase from $5.7 million in Q2 2025 [6][7] - GAAP gross profit for Q3 2025 was $2.7 million, or 43.7% of revenue, compared to $2.2 million, or 36.2% of revenue in Q3 2024, driven by lower production costs [9][10] - GAAP operating loss for Q3 2025 was $3.1 million, a slight improvement from $3.2 million in Q3 2024, while non-GAAP operating loss was $3 million compared to $4.1 million in the same period last year [11][12] Business Line Data and Key Metrics Changes - Revenue from traditional products, including ReWalk, MyoCycle, and ReStore, totaled $3.1 million in Q3 2025, up 24% from $2.5 million in Q3 2024, driven by increased Medicare-related sales [8] - Revenue from AlterG products decreased to $3.1 million in Q3 2025 from $3.6 million in Q3 2024, primarily due to timing factors [8] Market Data and Key Metrics Changes - Lifeward expanded patient access with the first Medicare Advantage commercial revenue for the ReWalk 7 personal exoskeleton and received CE mark approval, enhancing access to the European market, which represents about 40% of the global addressable exoskeleton opportunity [4][12] - The company closed the quarter with a pipeline of over 117 qualified leads for ReWalk in the U.S. and 49 leads in Germany, including 33 active rentals [8] Company Strategy and Development Direction - The company is focused on rebuilding fundamentals, defining strategic direction, and improving operational discipline, with a commitment to creating durable long-term value [3][5] - Lifeward is exploring global expansion opportunities and strategic partnerships to enhance financial position and market access [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing transformation and the potential for growth, emphasizing the importance of operational efficiencies and a focused sales approach [5][12] - The company reaffirmed its full-year 2025 guidance, expecting revenue in the range of $24-$26 million and a projected non-GAAP net loss of $12-$14 million [12] Other Important Information - Lifeward completed a $3 million loan agreement with AuraMed to enhance liquidity and support the transformation plan [4][12] - The company ended Q3 2025 with $2 million in cash and cash equivalents and no debt, indicating a stable financial position [11][12] Q&A Session Summary Question: Breakdown of rental systems for ReWalk - Lifeward confirmed that there are 33 active rentals, all in Germany [17] Question: Impact of collaboration with CoreLife - Management noted that the partnership with CoreLife is progressing well, with a growing pipeline and learning from training processes [19] Question: Percentage of revenue from Medicare - Medicare accounts for approximately 50% of total revenue, specifically for ReWalk products [21][24] Question: Revenue contribution from ReWalk within traditional product sales - Revenue from ReWalk products is approximately $2.9 million within the $3.1 million of traditional product sales [25] Question: Changes needed for AlterG to stabilize - Management indicated a need for a dedicated sales team for AlterG to regain focus and improve sales performance [38] Question: Introduction of ReWalk 7 in Germany - The company has a solid pipeline with 33 active rentals that are expected to convert to sales within three to six months [39] Question: Comfort level regarding financial stability - Management expressed optimism about the turnaround potential and the strength of the product portfolio, indicating a positive outlook for overcoming financial challenges [42]

Revenue Performance - Lifeward reported revenue of $6.2 million in Q3 2025, a slight increase of approximately 1% from $6.1 million in Q3 2024, and an 8% increase from $5.7 million in Q2 2025[5] - Revenue from traditional products, including ReWalk exoskeletons, increased by 24% year-over-year to $3.1 million, attributed to Medicare-related sales growth[5] - Revenue for Q3 2025 was $6,195 million, a slight increase from $6,128 million in Q3 2024, while total revenue for the nine months ended September 30, 2025, was $16,953 million, down from $18,118 million in the same period last year[23] Financial Losses and Improvements - Non-GAAP operating loss decreased to $3.0 million in Q3 2025, compared to a loss of $4.1 million in Q3 2024, representing a 27% improvement[7] - Operating loss for Q3 2025 was $(3,140) million, which is 50.7% of revenue, compared to $(3,174) million or 51.8% of revenue in Q3 2024[30] - Net loss for Q3 2025 was $(3,170) million, compared to $(3,084) million in Q3 2024, with a basic net loss per share of $(0.20) versus $(0.35) in the prior year[29] - Non-GAAP net loss for Q3 2025 was $(2,996) million, compared to $(3,960) million in Q3 2024, with a non-GAAP net loss per share of $(0.19) versus $(0.45) in the prior year[29] Cost Management and Efficiency - Quarterly cash burn improved to $3.8 million, down 16% year-over-year from $4.5 million in Q3 2024, reflecting operational efficiencies[4] - Operating expenses decreased to $5.7 million on a non-GAAP basis, down from $6.7 million in Q3 2024, reflecting improved efficiency in reimbursement activities[6] - Gross margin increased to 43.7% in Q3 2025, up from 36.2% in Q3 2024, driven by lower production costs following the closure of the Fremont facility[5] Cash Flow and Assets - Cash and cash equivalents at the end of Q3 2025 were $1,956 million, a decrease from $6,746 million at the end of December 2024[25] - Total assets as of September 30, 2025, were $23,168 million, down from $30,487 million at the end of December 2024[25] - The company reported net cash used in operating activities of $(13,271) million for the nine months ended September 30, 2025, compared to $(17,749) million in the same period of 2024[27] - The company experienced a decrease in cash, cash equivalents, and restricted cash of $(4,748) million for the nine months ended September 30, 2025, compared to $(17,778) million in the same period of 2024[27] Research and Development Expenses - Research and development expenses for Q3 2025 were $721 million, down from $998 million in Q3 2024, while sales and marketing expenses decreased to $3,168 million from $4,156 million[23] - GAAP research and development expenses for Q3 2025 were $721,000, representing 11.6% of revenue, compared to $998,000 (16.3%) in Q3 2024[31] - Non-GAAP research and development expenses for Q3 2025 were $689,000, or 11.1% of revenue, down from $960,000 (15.7%) in Q3 2024[31] General and Administrative Expenses - GAAP general and administrative expenses for Q3 2025 were $1,958,000, representing 31.6% of revenue, compared to $240,000 (3.9%) in Q3 2024[31] - Non-GAAP general and administrative expenses for Q3 2025 were $1,884,000, or 30.4% of revenue, compared to $2,024,000 (33.0%) in Q3 2024[31] - The company reported a significant increase in GAAP general and administrative expenses for the nine months ended September 30, 2025, totaling $5,917,000 (34.9%) compared to $3,424,000 (18.9%) in the same period of 2024[31] Strategic Initiatives - The company secured a $3.0 million loan from Oramed Ltd. to support ongoing operations and strategic initiatives[4] - Lifeward reaffirmed its full-year 2025 revenue guidance, expecting revenue in the range of $24 to $26 million and a projected non-GAAP net loss of $12 to $14 million[11] - The company received CE mark approval for the ReWalk 7 Personal Exoskeleton, enabling commercial sales in Europe, which currently accounts for approximately 40% of exoskeleton sales[4] Stock-Based Compensation - Stock-based compensation expenses for Q3 2025 were $74,000 (1.2%) compared to $158,000 (2.6%) in Q3 2024[31]

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medi ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets open on Friday, November 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a co ...

Group 1 - Chengdu's humanoid robot innovation center has developed the first domestic robot task execution system (R-WMES) based on a world model, marking a significant milestone in intelligent humanoid robot capabilities [2] - The world model framework mimics human brain thinking by learning physical and causal laws from the real world, enabling robots to autonomously plan and execute tasks based on target images [2] - The R-WMES system demonstrates strong adaptability and task completion in unfamiliar environments, addressing the intelligence gap in humanoid robots and accelerating their practical and commercial application [2] Group 2 - The Ministry of Industry and Information Technology (MIIT) stated that China has established a complete manufacturing capability for humanoid robots, covering key chips, components, and complete machines [5] - Since the 14th Five-Year Plan, 46 cities have been supported in new technology transformation pilot projects, resulting in over 230 excellent smart factories and 1,260 5G factories [5] - China's industrial robot installation accounted for over 50% of the global total, with significant improvements in energy consumption efficiency for products like steel and cement [5] Group 3 - Xingyuan Intelligent, a company focused on embodied intelligence, has completed a 200 million RMB angel round of financing to accelerate the development and commercialization of its embodied brain technology [6] - The company was incubated by the Beijing Academy of Artificial Intelligence and aims to create a universal embodied brain for the physical world, leveraging a team of top talents in the field [6] - The founding team includes experienced professionals from leading companies, establishing a closed-loop ecosystem of "technical barriers + commercial realization" [6] Group 4 - The Swiss Federal Institute of Technology Zurich has proposed an innovative control framework for legged robots that combines reinforcement learning and multi-head attention mechanisms, enabling precise control and 100% success in obstacle navigation [11] - This method enhances the robot's adaptability to complex terrains by dynamically adjusting its focus based on real-time motion states and environmental data [11] - Both GR-1 and ANYmal-D robots have shown excellent performance in experimental and real-world environments, opening up new possibilities for practical applications [11] Group 5 - Lifeward's seventh-generation personal exoskeleton, ReWalk 7, has received CE certification for the European market, marking a significant milestone in medical device innovation for spinal cord injury rehabilitation [12] - ReWalk 7 features cloud connectivity, allowing users to control the device and track usage data through a smartwatch and mobile app, enabling personalized rehabilitation goals [12] - The new system supports seamless transitions between indoor and outdoor environments and includes one-click activation for stairs and sidewalks, enhancing user independence [12]

Core Insights - Lifeward Ltd. (LFWD) has received CE mark approval for the ReWalk 7 Personal Exoskeleton, allowing for commercial sale in Europe, which constitutes approximately 40% of the company's exoskeleton sales [1][7] - The ReWalk 7 features enhancements such as cloud connectivity, push-button control, customizable walking speeds, and the ability to navigate stairs and curbs, making it unique in the market [2][7] - The company has established supply contracts with major insurance carriers in Germany, covering about 45% of individuals with statutory health insurance, facilitating reimbursement for the exoskeletons [3] Financial Performance - Following the CE approval announcement, Lifeward's shares rose by 2.2% in after-market trading, although the stock has declined by 68.9% year-to-date, contrasting with a 20.4% growth in the industry and a 10.8% gain in the S&P 500 [4] - The recent approvals and improved cash burn rate due to operational efficiencies may positively impact future revenues and share price [5] Product Development and Manufacturing - The ReWalk 7 was launched in the U.S. in April, with over 20 units installed, marking the highest quarterly total for Medicare beneficiaries since the fee schedule was established [8] - The company transitioned to in-house manufacturing of the ReWalk, resulting in cost savings, improved quality control, and greater production flexibility [9] Research and Partnerships - Lifeward concluded a research program under the Israel Innovation Authority's MAGNET incentive program, demonstrating a proof-of-concept prototype integrating AI for autonomous decision-making in future ReWalk models [10] - The company expanded its partnership with SportsMed Products Ltd. for distributing its AlterG product portfolio in the UAE and the Gulf Cooperation Council [11]

Core Insights - Lifeward Ltd. has made significant progress in securing Medicare reimbursement for its ReWalk 7 Personal Exoskeleton, marking a milestone in expanding access for individuals with spinal cord injuries [1][2] - The company has successfully received its first payment from a commercial Medicare Advantage Plan, indicating a growing acceptance of its innovative medical technology [1][2] - The Centers for Medicare & Medicaid Services (CMS) has established a reimbursement pathway for personal exoskeletons, which has streamlined the claims process, allowing for quicker approvals and payments [2] Company Overview - Lifeward is a leader in medical technology focused on transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [3] - The company's product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, showcasing its commitment to delivering groundbreaking solutions [3] - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, emphasizing its global reach and impact in the healthcare sector [3]